Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMAPALUMAB Cause Condition aggravated? 37 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Condition aggravated have been filed in association with EMAPALUMAB (GAMIFANT). This represents 21.4% of all adverse event reports for EMAPALUMAB.

37
Reports of Condition aggravated with EMAPALUMAB
21.4%
of all EMAPALUMAB reports
6
Deaths
24
Hospitalizations

How Dangerous Is Condition aggravated From EMAPALUMAB?

Of the 37 reports, 6 (16.2%) resulted in death, 24 (64.9%) required hospitalization, and 3 (8.1%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMAPALUMAB. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does EMAPALUMAB Cause?

Off label use (67) Drug ineffective (37) Haemophagocytic lymphohistiocytosis (33) Multiple organ dysfunction syndrome (22) Staphylococcal bacteraemia (17) Adrenal insufficiency (14) Drug reaction with eosinophilia and systemic symptoms (14) Respiratory failure (14) Pyrexia (12) Disseminated mucormycosis (11)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which EMAPALUMAB Alternatives Have Lower Condition aggravated Risk?

EMAPALUMAB vs EMAPALUMAB-LZSG EMAPALUMAB vs EMEND EMAPALUMAB vs EMICIZUMAB EMAPALUMAB vs EMICIZUMAB-KXWH EMAPALUMAB vs EMPAGLIFLOZIN

Related Pages

EMAPALUMAB Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated EMAPALUMAB Demographics